Theravance Biopharma Inc
TBPH11.320USD
+0.420+3.85%
Market hours （ET）Quotes delayed by 15 min
566.01MMarket Cap
LossP/E TTM
More Details of Theravance Biopharma Inc Company
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Company Info
Ticker SymbolTBPH
Company nameTheravance Biopharma Inc
IPO dateMay 16, 2014
CEOMr. Rick E. Winningham
Number of employees97
Security typeOrdinary Share
Fiscal year-endMay 16
AddressUgland House, South Church Street
CityGEORGE TOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryCayman Islands
Postal codeKY1-1104
Phone16508086000
Websitehttps://www.theravance.com/
Ticker SymbolTBPH
IPO dateMay 16, 2014
CEOMr. Rick E. Winningham
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-2.21%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
214.99K
+0.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
160.16K
-5.73%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
142.13K
-6.17%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
58.06K
+22.46%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Chairman of the Board
Independent Chairman of the Board
42.14K
+33.82%
Mr. Jeremy T. Grant
Mr. Jeremy T. Grant
Independent Director
Independent Director
28.54K
+59.52%
Mr. Dean Jonathan (Dean) Mitchell
Mr. Dean Jonathan (Dean) Mitchell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-2.21%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
214.99K
+0.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
160.16K
-5.73%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
142.13K
-6.17%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
U.S.
64.38M
0.00%
Europe
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
19.02%
Weiss Asset Management
14.91%
Newtyn Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
6.07%
Irenic Capital Management LP
5.52%
Other
44.96%
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
19.02%
Weiss Asset Management
14.91%
Newtyn Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
6.07%
Irenic Capital Management LP
5.52%
Other
44.96%
Shareholder Types
Shareholders
Proportion
Hedge Fund
59.93%
Investment Advisor
16.82%
Investment Advisor/Hedge Fund
11.60%
Individual Investor
4.71%
Research Firm
2.89%
Bank and Trust
0.23%
Pension Fund
0.19%
Venture Capital
0.04%
Insurance Company
0.03%
Other
3.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
288
48.24M
96.47%
-10.03M
2025Q1
306
49.02M
97.92%
-10.33M
2024Q4
307
49.22M
100.10%
-11.44M
2024Q3
311
50.46M
103.15%
-9.84M
2024Q2
312
51.86M
106.61%
-21.43M
2024Q1
304
56.26M
115.67%
-11.52M
2023Q4
301
56.96M
111.33%
-13.16M
2023Q3
314
59.36M
109.50%
-14.46M
2023Q2
331
61.03M
103.70%
-24.91M
2023Q1
329
68.16M
106.54%
-18.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madison Avenue Partners LP
9.51M
19.02%
--
--
Mar 31, 2025
Weiss Asset Management
7.46M
14.91%
--
--
Mar 31, 2025
Newtyn Management, LLC
4.76M
9.51%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.04M
6.07%
-127.84K
-4.04%
Mar 31, 2025
Irenic Capital Management LP
2.76M
5.52%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.08M
4.16%
+77.48K
+3.87%
Mar 31, 2025
Park West Asset Management LLC
1.80M
3.61%
+11.26K
+0.63%
Mar 31, 2025
Winningham (Rick E)
1.31M
2.61%
-29.60K
-2.21%
Jun 23, 2025
Oasis Management Company Ltd.
1.12M
2.24%
+3.17K
+0.28%
Mar 31, 2025
State Street Global Advisors (US)
1.07M
2.13%
-155.69K
-12.74%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
2%
Invesco NASDAQ Future Gen 200 ETF
0.54%
ALPS Medical Breakthroughs ETF
0.37%
Global X Aging Population ETF
0.35%
iShares U.S. Pharmaceuticals ETF
0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.15%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
View more
Virtus LifeSci Biotech Products ETF
Proportion2%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.54%
ALPS Medical Breakthroughs ETF
Proportion0.37%
Global X Aging Population ETF
Proportion0.35%
iShares U.S. Pharmaceuticals ETF
Proportion0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.15%
iShares Micro-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
